Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Quarterly Report · 10-Q

IO Biotech, Inc.

Quarterly Report

Filed May 14, 2024Accepted May 14, 2024, 8:13 AM EDTCIK 1865494Accession 0000950170-24-059108
Share

Company context

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).

Current securities

Historical securities (1)

Recent company filings

  1. 25-NSE - filed by Nasdaq Stock Market LLC regarding IO Biotech, Inc.Jun 8, 2026
  2. SCHEDULE 13D/A - filed by Lundbeckfond Invest A/S regarding IO Biotech, Inc.Jun 2, 2026
  3. SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding IO Biotech, Inc.May 15, 2026
  4. SCHEDULE 13G/A - filed by HBM Healthcare Investments (Cayman) Ltd. regarding IO Biotech, Inc.Apr 6, 2026
  5. Bankruptcy or Receivership · Triggering Events That Accelerate or Increase a Direct Financial Obligation · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsMar 31, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.